1
). In particular, expression of neuronal damage in the rat brain neocortex by gp120 is preceded by microglial cell activation and by an early (at 6 and 24 h from i.c.v. injection of a single dose of gp120) enhancement of IL-1b expression with more enhanced expression detectable after 7 days of treatment (see Corasaniti et al 1 ) . IL1b is synthesised as an inactive 31 kDa precursor molecule (pro-IL-1b) that is processed by caspase-1 (formerly referred to as interleukin-1 converting enzyme, ICE), to yield the mature, 17 kDa biologically active form of the cytokine. 2 Pharmacological manipulations indicate that abnormally elevated IL-1b plays a causative role in the expression of neuronal apoptosis yielded by HIV-1 gp120 in the brain neocortex of rat. 3 Thus, neuronal cell loss was minimised by Ac-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-cmk), a specific inhibitor of caspase 1 (see Corasaniti et al 1 ). In addition, protection from cell death was afforded by the endogenous antagonist of IL-1 receptor type I (IL-1ra), a molecule which inhibits most of the biological actions of IL-1b. 3 We report here that HIV-1 gp120 elevates cytochrome c immunoreactivity into the cell cytoplasm of rat brain neocortex and that this is an early event that occurs 6 h following a single i.c.v. injection of the viral protein. Interestingly, acetyl-TyrVal-Ala-Asp-2,6-dimethylbenzoyloxy-methylketone (Ac-YVAD-(acyloxy)mk), an inhibitor of caspase-1, 4 was able to counteract gp120-induced cytosolic cytochrome c elevation and this without affecting IL-1b levels. Collectively, these observations suggest that Ac-YVAD-(acyloxy)mk prevents cytochrome c expression into the cytosol through a mechanism independent from inhibition of IL-1b generation.
Ultrathin sections of rat brain neocortex labelled with anticytochrome c antibody were observed by transmission electron microscopy to study cytochrome c localisation. In tissue sections of brain neocortex from BSA (100 ng given i.c.v. 6 h before killing)-treated rats, anti-cytochrome c reactive epitopes are mainly localised into the mitochondria (see Figure 1a for a typical example). A quite different intracellular localisation of cytochrome c immunoreactivity is observed in brain neocortical sections from rats treated 6 h before with a single dose of gp120 (100 ng i.c.v.) in which the gold particles are visible in the mitochondria and throughout the cell cytoplasm (Figure 1b) . Likewise, enhanced cytochrome c immunoreactivity is also seen in cytosolic fractions obtained from individual brain cortical tissues of rats treated 6 h before with a single dose (100 ng i.c.v.) of gp120 and processed by Western blot technique (Figure 1d ). Interestingly, the latter effect is reduced by the caspase-1 inhibitor Ac-YVAD-(acyloxy)mk (50 pmol given i.c.v. 1 h before gp120) (Figure 1c and d) and this does not appear to be mediated via inhibition of IL-1b generation. In fact, Ac-YVAD-(acyloxy)mk is unable to affect cleavage of pro-IL-1 triggered by gp120 ( Figure 1f) ; consistently, Ac-YVAD-(acyloxy)mk also failed to reduce gp120-increased IL-1b levels (Figure 1e) .
The original observation that gp120 induces cytochrome c translocation in the brain neocortex of rats treated 6 h before with a single dose of the viral protein,that is, at a time when there is no evidence of cell loss (see Corasaniti et al 1 ) , suggests that release of cytochrome c is an early event in the pathway of neuronal cell demise triggered by the HIV-1 coat protein in vivo. To the best of our knowledge, this is the first in vivo evidence that an inhibitor of caspase-1 prevents cytochrome c translocation.
Cytochrome c, a member of the mitochondrial electrontransport chain, once released from the mitochondrial intermembrane space into the cytosol functions as a proapoptotic factor (see Kroemer and Reed 5 ). In vitro, cytochrome c translocation and caspase-8-and caspase-9-dependent activation of caspase-3 has been described in cerebrocortical neurons exposed to gp120 6 ; under these experimental conditions, relatively specific inhibitors of caspase cascade prevented gp120-induced apoptosis. Caspase-3-like immunoreactivity is elevated in cerebrocortical neurons from patients with HAD. 6 These observations suggest that caspases may represent potential targets for the prevention of neuronal damage induced by HIV-1.
Quite importantly, cytochrome c elevation into the cell cytosol of brain cortical tissue of gp120-treated rats is prevented by Ac-YVAD-(acyloxy)mk and this does not seem
to occur through inhibition of IL-1b generation (i.e. caspase-1 inhibition).
In a rat model of permanent middle cerebral artery occlusion, i.c.v. injection of Ac-YVAD-cmk afforded neuroprotection and reduced brain levels of IL-1b. 7 By contrast, in a rat model of endotoxaemia, Ac-YVAD-cmk reduced lethality induced by intravenous administration of LPS but it was unable to affect increased blood levels of IL-1b. 8 The ability or not of caspase-1 inhibitors to decrease the generation of IL-1b may be related to the fact that more than one proinflammatory caspase, that is, caspase-11 and caspase-5, may be involved in IL-1 processing (see Burns et al. 9 ). In addition, caspase-1 inhibitors are not selective for caspase-1, and proteases, other than caspases, involved in cell death, may be inhibited 10 ; then, it cannot be excluded that in our rat model of experimental neuroAIDS, prevention of cytochrome c translocation (present data) and minimisation of apoptotic neurons 3 by caspase-1 inhibitors may be unrelated to caspase-1 inhibition. Incidentally, in vitro inhibition of cathepsins by 'caspase-specific inhibitors', including Ac-YVAD-cmk, has been described 10 and there is evidence that inhibition of cathepsin B is implicated in the mechanisms through which Ac-YVAD-cmk rescues neurons from death induced by oxidative stress and oxygen/glucose deprivation. 11 In view of the established link between inhibition of cytochrome c translocation and neuroprotection, further experiments are in progress to characterise the molecular targets involved in the mechanisms underlying the observed inhibition of cytochrome c translocation by caspase-1 inhibitors in experimental neuroAIDS.
